Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sam Jackson

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences|January 21, 2020
Machine learning and big scientific dataTony Hey, Keith Butler, Sam Jackson, et al.
Vaccine|June 13, 2015
Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of ageJulia M Janssen, Sam Jackson, William L Heyward, et al.
Vaccine|April 10, 2018
Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adultsRandall Hyer, Darren K McGuire, Biao Xing, et al.
Autoimmunity|January 27, 2012
Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitisSharmilee Gnanapavan, Donna Grant, Gareth Pryce, et al.
Psychonomic Bulletin & Review|February 3, 2018
State anxiety and information processing: A 7.5% carbon dioxide challenge studyKayleigh E Easey, Jon C Catling, Christopher Kent, et al.
Journal of Neurochemistry|March 19, 2013
Progression in multiple sclerosis is associated with low endogenous NCAMSharmilee Gnanapavan, Peggy Ho, Wendy Heywood, et al.
Retina (Philadelphia, Pa.)|May 10, 2022
SAFETY AND THERAPEUTIC EFFECTS OF ORALLY ADMINISTERED AKST4290 IN NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONMichael W Stewart, Seema Garg, Erin M Newman, et al.
Vaccine|January 1, 2018
Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adultsSam Jackson, Joseph Lentino, James Kopp, et al.
Alzheimer'S & Dementia (New York, N. Y.)|December 21, 2020
Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's disease dementiaJonas Hannestad, Katie Koborsi, Vicki Klutzaritz, et al.
Clinical Pharmacology and Therapeutics|November 15, 2017
First-in-Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well-ToleratedSam Jackson, Albert F Candia, Stephen Delaney, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences|January 21, 2020
Machine learning and big scientific dataTony Hey, Keith Butler, Sam Jackson, et al.
Vaccine|June 13, 2015
Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of ageJulia M Janssen, Sam Jackson, William L Heyward, et al.
Vaccine|April 10, 2018
Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adultsRandall Hyer, Darren K McGuire, Biao Xing, et al.
Autoimmunity|January 27, 2012
Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitisSharmilee Gnanapavan, Donna Grant, Gareth Pryce, et al.
Psychonomic Bulletin & Review|February 3, 2018
State anxiety and information processing: A 7.5% carbon dioxide challenge studyKayleigh E Easey, Jon C Catling, Christopher Kent, et al.
Journal of Neurochemistry|March 19, 2013
Progression in multiple sclerosis is associated with low endogenous NCAMSharmilee Gnanapavan, Peggy Ho, Wendy Heywood, et al.
Retina (Philadelphia, Pa.)|May 10, 2022
SAFETY AND THERAPEUTIC EFFECTS OF ORALLY ADMINISTERED AKST4290 IN NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATIONMichael W Stewart, Seema Garg, Erin M Newman, et al.
Vaccine|January 1, 2018
Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adultsSam Jackson, Joseph Lentino, James Kopp, et al.
Alzheimer'S & Dementia (New York, N. Y.)|December 21, 2020
Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's disease dementiaJonas Hannestad, Katie Koborsi, Vicki Klutzaritz, et al.
Clinical Pharmacology and Therapeutics|November 15, 2017
First-in-Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well-ToleratedSam Jackson, Albert F Candia, Stephen Delaney, et al.
Pageof 2